Floatz logo

su011248

Advanced Lymphoma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Advanced Lymphoma cohort.

Asset / SponsorPhaseRating
Capivasertib
University of Chicago
Phase 2B
Trastuzumab Emtansine
Memorial Sloan Kettering Cancer Center
Phase 2B
Dasatinib
National Cancer Institute (NCI)
Phase 2B
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2B
Fexagratinib
National Cancer Institute (NCI)
Phase 2B

View all 31 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →